ARS Pharmaceuticals (SPRY) Receivables - Other (2021 - 2025)
ARS Pharmaceuticals (SPRY) has disclosed Receivables - Other for 5 consecutive years, with $4.3 million as the latest value for Q3 2025.
- Quarterly Receivables - Other rose 2708.55% to $4.3 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Sep 2025, up 2708.55% year-over-year, with the annual reading at $1.2 million for FY2024, 88.96% up from the prior year.
- Receivables - Other hit $4.3 million in Q3 2025 for ARS Pharmaceuticals, up from $2.0 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $4.3 million in Q3 2025 to a low of $122000.0 in Q2 2024.
- Historically, Receivables - Other has averaged $841000.0 across 5 years, with a median of $307000.0 in 2023.
- Biggest five-year swings in Receivables - Other: tumbled 65.04% in 2024 and later soared 2708.55% in 2025.
- Year by year, Receivables - Other stood at $159000.0 in 2021, then soared by 33.96% to $213000.0 in 2022, then skyrocketed by 206.1% to $652000.0 in 2023, then soared by 88.96% to $1.2 million in 2024, then soared by 246.51% to $4.3 million in 2025.
- Business Quant data shows Receivables - Other for SPRY at $4.3 million in Q3 2025, $2.0 million in Q2 2025, and $963000.0 in Q1 2025.